The adverse reactions reported in a 26-week, double-blind trial comparing oral ABILIFY and placebo in patients with schizophrenia were generally consistent with those reported in the short-term, placebo-controlled trials, except for a higher incidence of tremor [8% (12/153) for ABILIFY vs. 2% (3/153) for placebo]. In this study, the majority of the cases of tremor were of mild intensity (8/12 mild and 4/12 moderate), occurred early in therapy (9/12 ≤ 49 days), and were of limited duration (7/12 ≤ 10 days). Tremor infrequently led to discontinuation ( < 1%) of ABILIFY. In addition, in a long-term (52 week), active-controlled study, the incidence of tremor was 5% (40/859) for ABILIFY. A similar profile was observed in a long-term monotherapy study and a long-term adjunctive study with lithium and valproate in bipolar disorder.
Emily Taylor, despite being reunited with her husband from prison, becomes severely depressed with emotional episodes and suicide attempts. Her psychiatrist, Jonathan Banks, after conferring with her previous doctor, eventually prescribes an experimental new medication called Ablixa. The plot thickens when the side effects of the drug lead to Emily killing her husband in a "sleepwalking" state. With Emily plea-bargained into mental hospital confinement and Dr. Banks' practice crumbling around him, the case seems closed. However, Dr. Banks cannot accept full responsibility and investigates to clear his name. What follows is a dark quest that threatens to tear what's left of his life apart even as he discovers the diabolical truth of this tragedy. Written by Kenneth Chisholm (kchishol@)
*General Disclaimer / FTC Disclosure: Results discussed on this website are understood to be "generally expected results" in compliance with all FTC requirements. Any extraordinary results experienced by any individual are specified according to the scientific study that endorses it explicitly. Results will vary with each individual. Any results mentioned are assumed to be based on average patient results and are not based on extraordinary claims. If you should find any advertisements or claims to be unrealistic or extreme, please contact us and we will immediately review the content. Jes Extender makes every effort to ensure the quality of the information available on this website and updates the information regularly. The contents of this website have been prepared with great care, however, Jes Extender cannot assume any responsibility for its accuracy. Statements on this website have not been evaluated by the Food and Drug Administration. Jes Extender products are certified medical devices with safety and efficacy assessed under Medical Device Directive 93/42/EEC in Europe. Always read the product directions before use. As with other products, seek professional advice before using if you suffer material allergies and consult your doctor or pharmacist if you have an underlying medical condition or if on medication.